A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SB1578 When Administered Orally to Healthy Adult Subjects With One Single-Dose Group Crossing Over to Assess Food Effect.
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2012
At a glance
- Drugs CT 1578 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 19 Apr 2012 Actual patient number is 40 according to ClinicalTrials.gov.
- 19 Apr 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.